EVE Strengthens Scientific Board Amid Growing Dysmenorrhoea Market Risks
EVE Health Group has appointed Dr Fiona Cousins as the inaugural member of its Scientific Advisory Board, reinforcing its commitment to advancing treatments for dysmenorrhoea and endometriosis ahead of the commercial launch of Dyspro™.
- Dr Fiona Cousins joins as inaugural Scientific Advisory Board member
- Focus on reproductive health and women’s health pipeline
- Supports upcoming launch of Dyspro™, a cannabinoid-based dysmenorrhoea treatment
- Addresses significant market opportunity in dysmenorrhoea and endometriosis
- Strengthens EVE’s evidence-based innovation strategy
Strategic Appointment to Strengthen Scientific Leadership
EVE Health Group (ASX, EVE) has taken a decisive step to bolster its scientific credentials with the appointment of Dr Fiona Cousins as the first member of its newly formed Scientific Advisory Board (SAB). Dr Cousins brings over a decade of expertise in reproductive biology and women’s health, particularly in endometrial biology and endometriosis research, positioning her as a key asset for EVE’s evolving pipeline.
Her role on the SAB will be pivotal in guiding the company’s research and development efforts, especially as EVE prepares to launch Dyspro™, its proprietary cannabinoid-based gummy designed to treat dysmenorrhoea, a condition affecting a large proportion of women globally. This appointment signals EVE’s commitment to grounding its innovations in robust scientific evidence and clinical insight.
Addressing Under-Served Women’s Health Conditions
Dysmenorrhoea and endometriosis represent some of the most prevalent yet under-addressed conditions impacting women’s reproductive health. In Australia alone, painful menstruation affects up to 77% of women aged 18–44, with significant social and economic consequences including lost productivity estimated at AUD 14.2 billion annually. Endometriosis, a chronic inflammatory disease linked to severe pelvic pain, affects an estimated 14% of women of reproductive age and carries substantial healthcare and productivity costs.
By integrating Dr Cousins’ internationally recognised expertise, EVE aims to refine its product development strategies and regulatory positioning to better meet these unmet medical needs. The SAB will also provide broader guidance across EVE’s portfolio, which spans sexual, reproductive, men’s, and gut health.
Market Potential and Future Outlook
The global market for dysmenorrhoea treatments is robust and growing, valued at nearly USD 11 billion in 2024 and projected to reach USD 20 billion by 2035. Similarly, the Australian endometriosis treatment market is expected to expand rapidly, with a forecast CAGR of 13% through 2030. EVE’s strategic focus on these areas, supported by scientific leadership, positions the company to capture a meaningful share of this expanding market.
Executive Director and Chief Scientific Officer Dr Stuart Gunzburg highlighted the significance of Dr Cousins’ appointment as a milestone that strengthens the scientific foundation underpinning EVE’s growth strategy. Meanwhile, Dr Cousins expressed enthusiasm about contributing to EVE’s mission to develop evidence-based solutions that improve women’s reproductive health outcomes.
As EVE moves closer to the commercial launch of Dyspro™, investors and industry watchers will be keen to observe how this enhanced scientific advisory capability translates into clinical validation, regulatory progress, and market traction.
Bottom Line?
EVE’s appointment of Dr Cousins marks a strategic inflection point as it prepares to commercialise Dyspro™ and deepen its impact in women’s health.
Questions in the middle?
- How will Dr Cousins’ expertise influence the clinical development and regulatory approval of Dyspro™?
- What are the timelines and commercial expectations for Dyspro™’s market launch and uptake?
- Will EVE expand its Scientific Advisory Board with additional experts to cover other therapeutic areas?
